# Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)

> **NCT04274049** · PHASE3 · COMPLETED · sponsor: **Beijing Northland Biotech. Co., Ltd.** · enrollment: 242 (actual)

## Conditions studied

- Arterial Occlusive Disease
- Ischemia
- Ulcers
- Peripheral Vascular Disease

## Interventions

- **GENETIC:** NL003
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT04274049
- **Lead sponsor:** Beijing Northland Biotech. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-28
- **Primary completion:** 2023-12-23
- **Final completion:** 2023-12-23
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04274049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04274049, "Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04274049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*